Reata Pharmaceuticals Announces Pricing of Class A Common Stock Public Offering
Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its underwritten public offering of 3,000,000 shares of its Class A common stock at a price to the public of $72.00 per share.
Reata develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.
The V&E corporate team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associates Desi Baca and Grace-Ann Duquette. Partner Jim Meyer and associate Glen Ellsworth advised on tax issues.
For more information, please speak with our media contacts.